View DividendSofWave Medical マネジメントマネジメント 基準チェック /44SofWave Medicalの CEO はLouis Scafuriで、 Jul2019年に任命され、 の在任期間は 6.92年です。 の年間総報酬は$ 1.26Mで、 51.2%給与と48.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.12%を直接所有しており、その価値は$ 602.71K 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と5.9年です。主要情報Louis Scafuri最高経営責任者US$1.3m報酬総額CEO給与比率51.19%CEO在任期間6.9yrsCEOの所有権0.1%経営陣の平均在職期間3.6yrs取締役会の平均在任期間5.9yrs経営陣の近況お知らせ • Mar 19SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026. Location: co. offices, Israelお知らせ • Mar 10SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025. Location: cpc buileding, yokneaml, Israelすべての更新を表示Recent updatesお知らせ • Mar 19SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026. Location: co. offices, Israelお知らせ • Mar 10SofWave Medical Ltd. to Report Q4, 2025 Results on Mar 17, 2026SofWave Medical Ltd. announced that they will report Q4, 2025 results on Mar 17, 2026お知らせ • Jan 07SofWave Medical Ltd. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025SofWave Medical Ltd. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. for the quarter, the company expects total between $28.6 million and $28.9 million, as compared to approximately $18.3 million in the same period last year, reflecting an increase of approximately 57% compared to the same period last year. for the year, revenue is expected to total between $87.3 million and $87.6 million, as compared to approximately $59.7 million in the same period last year, reflecting an increase of approximately 46% compared to the same period last year.お知らせ • Oct 20SofWave Medical Ltd. to Report Q3, 2025 Results on Nov 04, 2025SofWave Medical Ltd. announced that they will report Q3, 2025 results on Nov 04, 2025お知らせ • Sep 04Sofwave Medical Ltd. Receives FDA, Pre-market Clearance for Pure Impact VIP Standalone EMS Device for Comprehensive Multi-Body Area Muscle Strengthening and FirmingSofwave Medical Ltd. announced that the Company has received 510(k) premarket notification clearance from the U.S. Food and Drug Administration (FDA). This clearance expands the Pure Impact™? product line further via the launch of a standalone EMS Device branded Pure Impact VIP™?. The Pure Impact VIP™? is designed as a standalone system that can be delegated and administered by staff using a simple and intuitive procedure.お知らせ • Aug 12Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million.Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million on August 7, 2025. A cash consideration valued at ILS 27.12 per share will be paid by Migdal Insurance. Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) completed the acquisition of 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) on August 7, 2025.お知らせ • Jul 16SofWave Medical Ltd. to Report Q2, 2025 Results on Aug 05, 2025SofWave Medical Ltd. announced that they will report Q2, 2025 results on Aug 05, 2025お知らせ • Apr 25Sofwave’S Lifthd Body Contouring Applicator to Debut At the 44Th Annual Meeting of the American Society for Laser Medicine and Surgery (Aslms) 2025SofWave Medical Ltd. announced activities around the official launch of the liftHD high density body contouring handpiece at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025 on energy-based medicine and science being held at the Orange County convention Center in Orlando, Florida, from April 24- 26, 2025. Sofwave’s onsite exhibition booth will be active throughout the event, showcasing the liftHD non-invasive aesthetic body contouring applicator as well as the Sofwave family of SUPERB™ and Pure Impact™ product lines. The new body contouring applicator benefits patients by utilizing the same precise SUPERB™ pulse technology as with the SUPERB™ line of treatments but with broader, higher density controlled thermal zones resulting in less pulses per treatment, thereby reducing treatment time by ~40%. The liftHD applicator by Sofwave is the Company’s newest applicator and provides the opportunity to deliver next generation non-invasive aesthetic body treatments which improve cellulite and skin laxity appearance to achieve SUPERB results beyond the face. This body applicator’s user-friendly, ergonomic design was specifically made to deliver fast, efficient, comfortable treatments. SUPERB™ Treatment Technology is Not Only Different But Better than the Competition.Precise depth control – The thermal treatment zone is precisely placed between 0.5mm and 1.8 mm to stimulate natural healing and collagen, elastin, and hyaluronic acid production. Optimized Energy Delivery - Optimal dermal timulation is achieved by parallel heating the dermis to a temperature of 149-158°F for a controlled, predictable, and dermally selective treatment outcome.Unique Broad Tissue Coverage - Seven parallel beam transducers simultaneously create large, controlled 3D cylindrical thermal zones with each pulse, resulting in optimal treatment coverage in just one 30–45-minute treatment. In addition, clinicians continue to expand the body of clinical evidence and case studies which strongly supporting the benefits of the Sofwave™ family of products and treatments.お知らせ • Apr 21Sofwave Medical Ltd.'s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC RegionSofwave Medical Ltd. announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has granted the Company approval to commercially market Sofwave's SUPERB™? Technology. Market approval in Japan further extends Sofwave's sales reach in the APAC territories, which now comprises major regional medical aesthetic device markets, including Japan, Australia, Taiwan, and South Korea.お知らせ • Mar 10SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025. Location: cpc buileding, yokneaml, Israelお知らせ • Jan 14Sofwave Medical Provides Earnings Guidance for Fourth Quarter and Full Year 2024Sofwave Medical Provided Earnings Guidance for fourth quarter and full year 2024. For the quarter, the company expects revenue to total between $18.2 million and $18.4 million, as compared to approximately $15.3 million in the same period last year, reflecting an increase of approximately 20% compared to the same period last year. For the full year 2024, the company expects revenue to total between $59.5 million and $59.7 million, as compared to approximately $50.3 million in the same period last year, reflecting an increase of approximately 19% compared to the same period last year.CEO報酬分析SofWave Medical の収益と比較して、Louis Scafuri の報酬はどのように変化したか？日付総報酬給与会社業績Mar 31 2026n/an/aUS$8mDec 31 2025US$1mUS$645kUS$5mSep 30 2025n/an/aUS$684kJun 30 2025n/an/a-US$2mMar 31 2025n/an/a-US$5mDec 31 2024US$981kUS$592k-US$5mSep 30 2024n/an/a-US$4mJun 30 2024n/an/a-US$4mMar 31 2024n/an/a-US$5mDec 31 2023US$1mUS$547k-US$8mSep 30 2023n/an/a-US$12mJun 30 2023n/an/a-US$15mMar 31 2023n/an/a-US$18mDec 31 2022US$837kUS$508k-US$20m報酬と市場: Louisの 総報酬 ($USD 1.26M ) は、 US市場 ($USD 2.51M ) の同様の規模の企業の平均を下回っています。報酬と収益: Louisの報酬は、過去 1 年間の会社の業績と一致しています。CEOLouis Scafuri (74 yo)6.9yrs在職期間US$1,260,000報酬Mr. Louis Scafuri serves as the Chief Executive Officer at SofWave Medical Ltd.リーダーシップ・チーム名称ポジション在職期間報酬所有権Louis ScafuriChief Executive Officer6.9yrsUS$1.26m0.12% $ 602.7kAssaf KornerChief Financial Officer4.8yrsUS$1.19m0.089% $ 448.9kJames BartholomeuszChief Innovation Officer2.3yrsUS$904.00kデータなしLIna OmariChief Digital Officer2.4yrsUS$714.00kデータなしMiguel PardosChief Commercial Officer1.6yrsUS$1.45mデータなしShimon EckhouseCo-Founder & Chairman11.4yrsデータなし23.61% $ 119.6mAriel SverdlikCo-Founder & CTO11.3yrsUS$336.00k9.22% $ 46.7mRuthie AmirChief Medical Officer7.4yrsUS$310.00kデータなしLarry LaberExecutive VP of North American Sales1.8yrsデータなしデータなしTali MalachVice President of Qualityno dataデータなしデータなしもっと見る3.6yrs平均在職期間56yo平均年齢経験豊富な経営陣: SOFW.Fの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。取締役名称ポジション在職期間報酬所有権Shimon EckhouseCo-Founder & Chairman11.4yrsデータなし23.61% $ 119.6mLisa HaimovitzIndependent Outside Director5.1yrsデータなし0.0066% $ 33.5kDominick ArenaIndependent Director7.4yrsデータなし1% $ 5.1mOrly ZilbermanExternal Director4.8yrsデータなしデータなしSarit Soukari Ben YohenanExternal Director4.8yrsデータなしデータなしAssaf MansourDirector6.8yrsデータなし0.10% $ 525.6kもっと見る5.9yrs平均在職期間64yo平均年齢経験豊富なボード: SOFW.Fの 取締役会 は 経験豊富 であると考えられます ( 5.9年の平均在任期間)。View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 21:17終値2026/05/28 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SofWave Medical Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 19SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026. Location: co. offices, Israel
お知らせ • Mar 10SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025. Location: cpc buileding, yokneaml, Israel
お知らせ • Mar 19SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026SofWave Medical Ltd., Annual General Meeting, Apr 23, 2026. Location: co. offices, Israel
お知らせ • Mar 10SofWave Medical Ltd. to Report Q4, 2025 Results on Mar 17, 2026SofWave Medical Ltd. announced that they will report Q4, 2025 results on Mar 17, 2026
お知らせ • Jan 07SofWave Medical Ltd. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025SofWave Medical Ltd. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. for the quarter, the company expects total between $28.6 million and $28.9 million, as compared to approximately $18.3 million in the same period last year, reflecting an increase of approximately 57% compared to the same period last year. for the year, revenue is expected to total between $87.3 million and $87.6 million, as compared to approximately $59.7 million in the same period last year, reflecting an increase of approximately 46% compared to the same period last year.
お知らせ • Oct 20SofWave Medical Ltd. to Report Q3, 2025 Results on Nov 04, 2025SofWave Medical Ltd. announced that they will report Q3, 2025 results on Nov 04, 2025
お知らせ • Sep 04Sofwave Medical Ltd. Receives FDA, Pre-market Clearance for Pure Impact VIP Standalone EMS Device for Comprehensive Multi-Body Area Muscle Strengthening and FirmingSofwave Medical Ltd. announced that the Company has received 510(k) premarket notification clearance from the U.S. Food and Drug Administration (FDA). This clearance expands the Pure Impact™? product line further via the launch of a standalone EMS Device branded Pure Impact VIP™?. The Pure Impact VIP™? is designed as a standalone system that can be delegated and administered by staff using a simple and intuitive procedure.
お知らせ • Aug 12Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million.Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) acquired 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) for ILS 37.6 million on August 7, 2025. A cash consideration valued at ILS 27.12 per share will be paid by Migdal Insurance. Migdal Insurance and Financial Holdings Ltd. (TASE:MGDL) completed the acquisition of 3.96% stake in SofWave Medical Ltd. (TASE:SOFW) on August 7, 2025.
お知らせ • Jul 16SofWave Medical Ltd. to Report Q2, 2025 Results on Aug 05, 2025SofWave Medical Ltd. announced that they will report Q2, 2025 results on Aug 05, 2025
お知らせ • Apr 25Sofwave’S Lifthd Body Contouring Applicator to Debut At the 44Th Annual Meeting of the American Society for Laser Medicine and Surgery (Aslms) 2025SofWave Medical Ltd. announced activities around the official launch of the liftHD high density body contouring handpiece at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025 on energy-based medicine and science being held at the Orange County convention Center in Orlando, Florida, from April 24- 26, 2025. Sofwave’s onsite exhibition booth will be active throughout the event, showcasing the liftHD non-invasive aesthetic body contouring applicator as well as the Sofwave family of SUPERB™ and Pure Impact™ product lines. The new body contouring applicator benefits patients by utilizing the same precise SUPERB™ pulse technology as with the SUPERB™ line of treatments but with broader, higher density controlled thermal zones resulting in less pulses per treatment, thereby reducing treatment time by ~40%. The liftHD applicator by Sofwave is the Company’s newest applicator and provides the opportunity to deliver next generation non-invasive aesthetic body treatments which improve cellulite and skin laxity appearance to achieve SUPERB results beyond the face. This body applicator’s user-friendly, ergonomic design was specifically made to deliver fast, efficient, comfortable treatments. SUPERB™ Treatment Technology is Not Only Different But Better than the Competition.Precise depth control – The thermal treatment zone is precisely placed between 0.5mm and 1.8 mm to stimulate natural healing and collagen, elastin, and hyaluronic acid production. Optimized Energy Delivery - Optimal dermal timulation is achieved by parallel heating the dermis to a temperature of 149-158°F for a controlled, predictable, and dermally selective treatment outcome.Unique Broad Tissue Coverage - Seven parallel beam transducers simultaneously create large, controlled 3D cylindrical thermal zones with each pulse, resulting in optimal treatment coverage in just one 30–45-minute treatment. In addition, clinicians continue to expand the body of clinical evidence and case studies which strongly supporting the benefits of the Sofwave™ family of products and treatments.
お知らせ • Apr 21Sofwave Medical Ltd.'s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC RegionSofwave Medical Ltd. announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has granted the Company approval to commercially market Sofwave's SUPERB™? Technology. Market approval in Japan further extends Sofwave's sales reach in the APAC territories, which now comprises major regional medical aesthetic device markets, including Japan, Australia, Taiwan, and South Korea.
お知らせ • Mar 10SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025SofWave Medical Ltd., Annual General Meeting, Apr 15, 2025. Location: cpc buileding, yokneaml, Israel
お知らせ • Jan 14Sofwave Medical Provides Earnings Guidance for Fourth Quarter and Full Year 2024Sofwave Medical Provided Earnings Guidance for fourth quarter and full year 2024. For the quarter, the company expects revenue to total between $18.2 million and $18.4 million, as compared to approximately $15.3 million in the same period last year, reflecting an increase of approximately 20% compared to the same period last year. For the full year 2024, the company expects revenue to total between $59.5 million and $59.7 million, as compared to approximately $50.3 million in the same period last year, reflecting an increase of approximately 19% compared to the same period last year.